Boston Scientific Corporation
BSX
$51.20
$0.741.46%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.67B | 3.57B | 2.90B | 2.79B | 2.51B |
| Total Depreciation and Amortization | 1.41B | 1.39B | 1.37B | 1.35B | 1.32B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 84.00M | -135.00M | 514.00M | 561.00M | 420.00M |
| Change in Net Operating Assets | -642.00M | -483.00M | -246.00M | -77.00M | 45.00M |
| Cash from Operations | 4.53B | 4.34B | 4.53B | 4.63B | 4.29B |
| Capital Expenditure | -904.00M | -866.00M | -876.00M | -802.00M | -800.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.06B | -1.88B | -1.59B | -4.92B | -5.79B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.59B | 12.00M | -171.00M | -108.00M | -164.00M |
| Cash from Investing | -3.56B | -2.73B | -2.64B | -5.83B | -6.76B |
| Total Debt Issued | 1.68B | 1.00M | 1.56B | 1.75B | 1.75B |
| Total Debt Repaid | -696.00M | -997.00M | -2.05B | -1.84B | -1.63B |
| Issuance of Common Stock | 221.00M | 248.00M | 282.00M | 290.00M | 271.00M |
| Repurchase of Common Stock | -2.00B | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -158.00M | -140.00M | -187.00M | -193.00M | -278.00M |
| Cash from Financing | -958.00M | -888.00M | -395.00M | 3.00M | 114.00M |
| Foreign Exchange rate Adjustments | 2.00M | 3.00M | 42.00M | 30.00M | 38.00M |
| Miscellaneous Cash Flow Adjustments | 0.00 | -1.00M | -- | -1.00M | -2.00M |
| Net Change in Cash | 12.00M | 724.00M | 1.54B | -1.17B | -2.32B |